“Working alongside the pharmaceutical industry really allows you to stay up to date with the latest and most-interesting innovations within biotechnology.”

60 seconds with Nick Stringfellow, Analyst

Q: Tell us about you

A: I developed an interest in science and innovation from a young age, as both of my parents have a medical profession. This interest led me to go onto study a bachelors in Biology at the University of Manchester (UoM), which opened my eyes to the astounding developments in medical research. During my studies, I began to realise that I wanted to pursue a career in the commercial side of Biology. I therefore decided to continue at UoM to study a master’s in Biotechnology and Enterprise to better understand the regulatory and financial demands of the pharmaceutical industry. I believe this has set me up well for my career in market access consultancy here at Lightning Health.

In my free time I try to spend as much time outdoors as possible either hiking, running, cycling, and occasionally riding horses. I’m also enjoying having recently moved to London and exploring my new local area and the accompanying nightlife. Before moving to London I was a keen gardener, which has subsequently manifested into me trying to turn my flat into a jungle of houseplants!

Q: What is your role at Lightning Health?

A: At Lightning Health I am currently working as an Analyst. This consists of assisting in project work including taking part in client meetings, conducting desk research, handling data, and presenting complex information in coherent formats. At Lightning Health, you have the support of a well-skilled team of consultants and senior analysts on all projects, which is really important for your development. I have already begun working on a range of project types and having an interest in the scientific background really helps bring the work to life.


Q: Tell us more about your studies.

A: During my master’s business project, we were tasked with developing a novel electronic biosensor using patented technology owned by UoM. This required the identification of a disease where data suggested a significant financial benefit in improving early patient diagnosis. We then explored biomarkers for the disease that could be detected by complementary molecules adhered to the surface of the biosensor, which the technology allowed to be detected at extremely low concentrations. All aspects of development had to be considered including the design and cost of clinical trials; market selection based on regulatory requirements and patient demographics; and pricing of the device based on manufacturing costs and the price of competitors within the chosen market. Overall, the project gave me experience in accessing country specific regulatory information, as well as an understanding of the financial implications faced by pharmaceutical companies at the various stages of medical product development. This experience has already proven useful to the project work I have worked on since joining Lightning Health.



Article published 11 January 2023.